The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Abstract
Background Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve markers of metabolism and liver fibrosis in obese patients with type 2 diabetes. In this phase 2a study, we aimed to evaluate the safety and efficacy of pegbelfermin in patients with non-alcoholic steatohepatitis.Methods In this multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2a study, we recruited adults (aged 21-75 years) with a body-mass index of at least 25 kg/m 2, biopsy-confirmed non-alcoholic steatohepatitis (fibrosis stage 1-3), and a hepatic fat fraction of at least 10% when assessed by magnetic resonance imaging-proton density fat fraction. These patients were enrolled at 17 medical centres in the USA. Eligible patients were stratified by type 2 diabetes status and they were randomly assigned (1:1:1) by a computer-based system to receive subcutaneous injections of placebo once a day, 10 mg pegbelfermin once a day, or 20 mg pegbelfermin once a week, all for 16 weeks. Participants, the study team administering treatment, and investigators analysing outcomes (who were independent of the study team and had no further involvement) were masked to treatment groups. The primary outcomes were safety and the absolute change in hepatic fat fraction after 16 weeks of treatment. All patients who were randomly assigned to groups and received the study drug or placebo were included in the primary analyses. This trial was registered with ClinicalTrials.gov, number NCT02413372.Findings Between May 12, 2015, and Aug 4, 2016, 184 overweight or obese patients with non-alcoholic steatohepatitis were screened for study inclusion. Of these, 95 (52%) patients were excluded because they no longer met study criteria and 80 (43%) patients entered the placebo lead-in phase. After further exclusions, 75 (94%) patients were randomly assigned to groups, received at least one dose of treatment (25 patients to receive 10 mg pegbelfermin once a day; 24 patients to receive 20 mg pegbelfermin once a week, and 26 patients to receive placebo), and were included in the primary analysis. A prespecified interim analysis at week 8 showed a greater than expected change in the primary outcome and supported early closing of patient enrolment, since this analysis indicated that the full planned sample size was not needed. We observed a significant decrease in absolute hepatic fat fraction in the group receiving 10 mg pegbelfermin daily (-6·8% vs -1·3%; p=0·0004) and in the group receiving 20 mg pegbelfermin weekly (-5·2% vs -1·3%; p=0·008) compared with the placebo group. Most adverse events were mild; the most common events were diarrhoea in eight (16%) of 49 patients treated with pegbelfermin and two (8%) of 26 patients treated with placebo and nausea in seven (14%) patients treated with pegbelfermin and two (8%) patients treated with placebo. There were no deaths, discontinuations due to adverse events, or treatment-related serious adverse events.Interpretation Treatment with subcutaneously administered pegbelfermin for 16 weeks was generally well tolerated and significantly reduced hepatic fat fraction in patients with non-alcoholic steatohepatitis. Further study of pegbelfermin is warranted in patients with non-alcoholic steatohepatitis. Additional studies that use liver biopsies would allow for the assessment of pegbelfermin's effects on liver histology. Moreover, further studies should allow assessments of the safety and effectiveness of pegbelfermin in a larger number of patients.Funding Bristol-Myers Squibb.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pegbelfermin showed a reduction in hepatic fat (measured via MRI‐PDFF) and liver transaminases over a 16‐week treatment period as well as an improved lipid profile; [53] however, no histological readouts were available which hampers applicability of the results and warrants further studies on this compound.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [53]
In the citing paper
“Pegbelfermin showed a reduction in hepatic fat (measured via MRI‐PDFF) and liver transaminases over a 16‐week treatment period as well as an improved lipid profile; [53] however, no histological readouts were available which hampers applicability of the results and warrants further studies on this compound.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [53]
In the citing paper
“all analogues consistently have a pronounced ability to decrease plasma triglyceride levels, in many cases by as much as ~70% (refs. 81,87–91).”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“two other FGF21 analogues, AKR-001 (also known as efruxifermin)88 and pegbelfermin89,90, have not been found to significantly decrease body weight in people with obesity or type 2 diabetes.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“the magnitude of the glucose-lowering effects of FGF21 analogues is clearly lower in humans than rodents81,87–91, perhaps because of differences in brown adipose tissue metabolism between species65.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“Administration of the FGF21 analogues AKR-001 (ref. 88) and pegbelfermin89 in humans with NASH results in marked absolute decreases in liver fat (up to 70%) and significant amelioration of liver fibrosis88,89.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“clinical studies in patients with obesity and type 2 diabetes have found that FGF21-analogue administration markedly induces plasma adiponectin levels81,87–89”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“PF-05231023 has been found to increase markers of bone turnover in humans81, whereas AKR-001 (ref. 88) and pegbelfermin89 have not.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationBedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,146
Classification and Diagnosis of Diabetes
Fajans, S. S. (1990) · Medical Entomology and Zoology · Cited by 2,356
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,312
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Research works printed but not linked: 3
- Charles, 2016, A phase 1 study of BMS-986036 (pegylated FGF21) in healthy obese subjects, Hepatology, 64, 546A
- Krupinski, 2016, Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis, Hepatology, 64, 749A
- Leeming DJ, Nielsen MJ, Goodman Z, et al. Plasma collagen III type III (Pro-C3) levels associate with severity of histological features of non-alcoholic steatohepatitis and fibrosis within the screening population from the CENTAUR study. NASH Biomarkers Workshop; Washington, DC, USA; May 5, 2017.
Cited by
Sorted by citations
Items 401–500 of 549
Korkmaz, D., Konya, P. Ş., & Demirtürk, N. (2022) · Turkish Journal of Parasitology · doi:10.4274/tpd.galenos.2022.14633 · Cited by 5
Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease
Chen, Y., Zhang, Y., Jin, X., Hong, S., & Tian, H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150305 · Cited by 5
A two-strata energy flux system driven by a stress hormone prioritizes cardiac energetics
Rao, Z., Chen, Z., Bao, Y., Lu, Z., Tang, Y., Zhu, J., Ma, J., Dong, S., Shi, J., Sheng, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02402-9 · Cited by 6
Self-citationThe liver-bone axis: an emerging player in disease pathogenesis and therapeutic intervention
Han, S., Wei, Y., Yu, G., Jia, W., Liao, W., He, Y., Cheng, K., Zhao, J., Xiang, S., Zhang, W., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3207-5 · Cited by 5
Rama, K., Jahagirdar, V., & Sanyal, A. J. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s560034 · Cited by 6
Self-citationRasmussen, D. G. K., Hansen, M. K., Frederiksen, P., Luo, Y., Pehrsson, M., Neal, B. C., Karsdal, M. A., & Genovese, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15761 · Cited by 5
Self-citationTreating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 6
Self-citationDushay, J. R., & Lai, M. (2019) · Hepatology · doi:10.1002/hep.30789 · Cited by 5
Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis
Esteban, J. P., & Asgharpour, A. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.10.003 · Cited by 5
Hou, H.-W., Bishop, C. A., Huckauf, J., Broer, I., Klaus, S., Nausch, H., & Buyel, J. F. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.998596 · Cited by 5
Arnold, J., Idalsoaga, F. J., Díaz, L. A., Cabrera, D., Francisco Barrera, M., Arab, J. P., & Arrese, M. A. (2024) · Current Hepatology Reports · doi:10.1007/s11901-023-00629-0 · Cited by 5
Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database
Du, H., Huang, J., Wang, Y., Wang, C., Wang, Y., Hou, L., Li, Y., Li, Y., & Su, Q. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03732-2 · Cited by 5
Guo, X., Wang, C., Yang, T., Ma, W., Zhai, J., Zhao, T., Xu, T., Li, ., Liu, H., Sinclair, A. J., et al. (2022) · Nutrition · doi:10.1016/j.nut.2022.111659 · Cited by 5
Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis
Schattenberg, J. M. (2020) · Visceral Medicine · doi:10.1159/000507231 · Cited by 5
Huang, Y., Liu, B., Hu, C., & Lu, Y. (2025) · Protein & Cell · doi:10.1093/procel/pwaf027 · Cited by 4
Growth factor applications and clinical translation: advances and challenges
Tu, Y., Li, B., Zheng, S., Qu, G., Li, M., Li, S., & Shao, C. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2642893 · Cited by 6
Malandris, K., Papandreou, S., Vasilakou, D., Kakotrichi, P., Sarakapina, A., Kalopitas, G., Karagiannis, T., Γιουλεμέ, Ό., Bekiari, E., Liakos, A., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16559 · Cited by 5
Physiological and pathophysiological role of endocrine fibroblast growth factors
Łukawska, A., & Mulak, A. (2022) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2022-0045 · Cited by 4
Hjort, L., Albrechtsen, N. J. W., Minja, D. T. R., Rasmussen, C. B., Møller, S. L., Lusingu, J., Theander, T. G., Bygbjerg, I. C., Schmiegelow, C., & Grunnet, L. G. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad120 · Cited by 3
Exploring the potential of drug repurposing for liver diseases: A comprehensive study
Ali, F. E. M., Abdel‐Reheim, M. A., Hassanein, E. H. M., El‐Aziz, M. K. A., Althagafy, H. S., & Badran, K. S. A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122642 · Cited by 5
Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development
Kemas, A. M., Youhanna, S. C., & Lauschke, V. M. (2022) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2022.2053285 · Cited by 4
Feng, J. N., & Jin, T. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100422 · Cited by 4
Computer-aided engineering of stabilized fibroblast growth factor 21
Bourdonnaye, G. D. L., Ghazalova, T., Fojtík, P., Kutálková, K., Bednář, D., Damborský, J., Rotrekl, V., Štěpánková, V., & Chaloupková, R. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.02.001 · Cited by 4
Efficacy of fibroblast growth factor 21 in non‐alcoholic fatty liver disease in guinea pigs
Klæbel, J. H., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13705 · Cited by 4
Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
Brennan, P. N., The University of Edinburgh, C. F. R. M., NHS Tayside, N. H. A. M. S., The University of Dundee, D. O. M. A. C. M., Dillon, J. F., NHS Tayside, N. H. A. M. S., The University of Dundee, D. O. M. A. C. M., McCrimmon, R., NHS Tayside, N. H. A. M. S., & The University of Dundee, D. O. M. A. C. M. (2022) · European Endocrinology · doi:10.17925/ee.2022.18.2.148 · Cited by 3
Aaldijk, A. S., Struik, D., Driessen, S., Verzijl, C. R. C., Verheij, J., Nieuwdorp, M., Eilers, R. E., Wolters, J. C., Holleboom, A. G., & Jonker, J. W. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100745 · Cited by 3
Liang, L., Chen, J., Zhu, J., Kang, Z., Sun, B., & Zhang, Y. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c05665 · Cited by 3
Narem, R. S. R., Mathakala, V., Sallabathula, S. T., Peddiboyina, V., & Palempalli, U. M. D. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04618-7 · Cited by 5
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 4
Marshall, W. R., McDonnell, T., Green, D., Sinha, S., & Kalra, P. A. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106592 · Cited by 4
The role of fibroblast growth factor 21 in diabetes and metabolic dysfunction
Jaiswal, A., Nigam, C., Singh, G. N., & Gautam, A. K. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12132-y · Cited by 3
Szczepańska, E., Glinicki, P., Zgliczyński, W., Slowinska-Srzednicka, J., Jastrzębska, H., & Gietka‐Czernel, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.900034 · Cited by 3
How far are we from an approved drug for nonalcoholic steatohepatitis?
Méndez‐Sánchez, N., Pal, S. C., & Córdova‐Gallardo, J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206953 · Cited by 3
Nouveautés dans la stéatose non alcoolique du foie (NAFLD)
Barigou, M., Favre, L., Fraga, M. C., & Artru, F. (2020) · JMIG · doi:10.53738/revmed.2020.16.687.0586 · Cited by 3
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32480 · Cited by 3
Nuclear Receptors in Energy Metabolism
Walth-Hummel, A. A., Herzig, S., & Rohm, M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_4 · Cited by 4
Barazesh, M., Jalili, S., Akhzari, M., Faraji, F., & Khorramdin, E. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230417111247 · Cited by 3
Zhang, C., Sui, Y., Liu, S., & Yang, M. J. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00029 · Cited by 3
Lu, Y., Yu, B., Bu, Y., Lou, J., & Jin, Y. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1293336 · Cited by 3
Current and Emerging Treatments for Non-alcoholic Steatohepatitis
Horn, C. L., Ta, A. C., & Gunn, N. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00540-y · Cited by 3
Xu, X., Mendoza, A., Krumm, C. S., Su, S., Acuña, M., Bare, C. J., Holman, C. D., Cortopassi, M. D., Nicholls, H. T., Dartigue, V., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adk7971 · Cited by 3
Dong, W., Wang, Y., Li, H., Ma, H., Gong, Y., Luo, G., & Gao, X. (2025) · Metabolites · doi:10.3390/metabo15070433 · Cited by 2
Chen, Z., Liu, T., Huang, P., Liu, Y., Xu, S., Ding, J., Song, H., Yang, L., & Zheng, P. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177874 · Cited by 2
FGF21 alleviates diabetic vasculopathy with NF-κB suppression and fibrinolytic activation
Li, S., Gao, J., Song, Z., Fan, C., Zhang, W., Ma, T., Zhang, Q., & Li, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178224 · Cited by 2
Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 2
Ma, B., Liu, Y., ZHANG, H., Fang, Y., Xue, Y., Xue, J., Jiang, Z., Zhou, T., Hao, Y., Xie, F., et al. (2025) · Advanced Science · doi:10.1002/advs.202517672 · Cited by 4
Adipose tissue as a humoral–neuronal hub in metabolic regulation
Tsuji, T., & Tseng, Y. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01265-6 · Cited by 5
Albhaisi, S. A. M., & Sanyal, A. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00121-3 · Cited by 2
Self-citationBentsa, T. М. (2023) · Modern Gastroenterology · doi:10.30978/mg-2023-6-59 · Cited by 3
Wei, L., Long, P., Ye, X., Zhu, S., & Cui, S. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104394 · Cited by 2
de Oliveira, F. D., Khalil, S. M., Sato, E. D. B. D. S., de Souza, M. H. G., & Meine, G. C. (2024) · Annals of Nutrition and Metabolism · doi:10.1159/000541583 · Cited by 2
Novel FGF21 analogues through structure-based optimization for therapeutic development
Guo, Y., Bao, Y., Chen, Z., Rao, Z., Luo, Y., Ye, S., & Liu, S. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024227 · Cited by 2
Self-citationLei, L., Li, H., Wang, X., Li, J., Sun, H., Li, H., Li, J., Tang, M., Xu, J.-C., Dong, B., et al. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.103305 · Cited by 3
MOB1 deletion in murine mature adipocytes ameliorates obesity and diabetes
Nishio, M., Yamaguchi, K., Otani, J., Yuguchi, K., Kohno, D., Sasaki, T., Kitamura, T., Shinohara, M., Soga, T., Kawamura, K., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2424741122 · Cited by 3
Huijbers, A., Korzilius, J. W., Morsche, R. T., van der Graaf, M., & Wanten, G. J. A. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.04.017 · Cited by 2
Blinding in Clinical Trials for Chronic Liver Diseases
Ortiz, V., Ellenberg, S. S., & Weinberg, E. M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723753 · Cited by 2
Watanabe, S., Shibukawa, S., Hayashi, T., Tsuruya, K., & Niwa, T. (2021) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2021.08.001 · Cited by 2
Iwaki, M., Kessoku, T., Tanaka, K., Ozaki, A., Kasai, Y., Yamamoto, A., Takahashi, K., Kobayashi, T., Nogami, A., Honda, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060335 · Cited by 2
A Polymorphism in the FGF21 Gene is a Novel Risk Variant for Metabolic-Associated Steatohepatitis
Elsayed, A. (2020) · The Sydney eScholarship Repository (The University of Sydney) · Cited by 2
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., Koehler, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522509 · Cited by 2
Imbalanced Skeletal Muscle Mitochondrial Proteostasis Causes Bone LossPreprint
Jin, Z., Mao, Y., Guo, Q., Yin, Y., Kiram, A., Zhou, D., Yang, J., Zhou, Z., Xue, J., Feng, Z., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4782549 · Cited by 2
Caon, E., Forlano, R., Mullish, B. H., Manousou, P., & Rombouts, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00025-5 · Cited by 1
Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 1
Corbalan, J. J., Petronella, B. A., Huang, C., Beasley, J. R., Merritt, J. R., Mugrage, B., & Nickels, J. T. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152360 · Cited by 1
Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024
Camilleri, M., & Dellon, E. S. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.06.001 · Cited by 1
Alzaki, A. A., Alqahtani, M., Aman, E., Asiri, G. M., Jibril, M. H. A., Desoky, R. M., Alqahtani, S. A., Suhaqi, L., Alkhalid, S. A., Alshareef, D. Y., et al. (2026) · Cureus · doi:10.7759/cureus.106038 · Cited by 2
Tsutsumi, T., Tang, N. S. Y., Ng, C. H., Suzuki, H., Syn, N. L., Sasikumar, N. A., Ho, G. J. K., Chua, D., Tioh, J. K., Pramotedham, T., et al. (2026) · Med · doi:10.1016/j.medj.2026.101077 · Cited by 1
Self-citation吴学碧, Ma, Y., Yin, X., Liu, J., & Zhang, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863710 · Cited by 1
Chen, Y., Yang, X., Shen, W., Zhang, P., Yang, X., Xu, X., & Lu, D. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70347 · Cited by 1
Zhong, S., Meng, X.-H., Xiang, Z., Qiu, G.-W., Sun, S.-T., Xie, J., & Xiao, L.-B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1875220 · Cited by 1
Wali, J. A., Ramos-Nieves, J. M., Binia, A., & van der Beek, E. M. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100713 · Cited by 1
Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root
Aggarwal, P., Singh, T., & Alkhouri, N. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00533-x · Cited by 1
Rating Agencies: Creating, Amplifying or Drawn by Events in the Sovereign Debt Crisis?
Url, T. (2012) · Austrian Economic Quarterly · Cited by 1
Lønsmann, I., Pehrsson, M., Nielsen, M. J., Villesen, I. F., Sinkevičiūtė, D., Bay‐Jensen, A., & Karsdal, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15617-5.00031-7 · Cited by 2
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis
Iwaki, M., Yoneda, M., Wada, N., Otani, T., Kobayashi, T., Nogami, A., Saito, S., & Nakajima, A. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2328036 · Cited by 1
Candidate molecular targets uncovered in mouse lifespan extension studies
Vedunova, M. V., Borysova, O., Kozlov, G., Zharova, A.-M. D., Morgunov, I., & Moskalev, A. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2346597 · Cited by 1
Karunaratna, A., & Ekanayake, S. (2024) · The Natural Products Journal · doi:10.2174/0122103155308948240528050738 · Cited by 1
Ayesh, H., & Olajide, O. B. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001814 · Cited by 1
Ali, M. H., Rehman, O. U., Talha, M., Fatima, E., Fatima, L., Zain, A., & Haisbuzzaman, M. A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002649 · Cited by 1
Wang, X., Meng, Q., Jia, A., Zhou, Y., Song, D., Ma, S., Li, W., Zhang, Z., Goldring, C. E., Feng, H., et al. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-05107-x · Cited by 1
Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article
Ahadi, S., Gharekhani, A., & Shiva, A. (2019) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2019.11.004 · Cited by 1
Spezifische Therapie – neue Medikamente
Lange, N. F., & Dufour, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_21 · Cited by 1
Tacke, F. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_36 · Cited by 1
Carrascosa, J. M., Vilarrasa, E., Belinchón, I., Herranz, P., Crespo, J., Guimerá, F., & Olveira, A. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.04.013 · Cited by 1
Li, L., Sun, H., Chen, J., Ding, C., Yang, X., Han, H., & Sun, Q. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.22.513320 · Cited by 1
Liu, C., Schönke, M., Spoorenberg, B., Lambooij, J. M., van der Zande, H. J. P., Zhou, E., Tushuizen, M. E., Andréasson, A., Park, A., Oldham, S. N., et al. (2023) · eLife · doi:10.7554/elife.83075.sa2 · Cited by 1
Larson, K. R., Jayakrishnan, D., Sauza, K. A. S., Goodson, M. L., CHAFFIN, A. T. B., Davidyan, A., Pathak, S. J., Fang, Y., Magaña, D. G., Miller, B. F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.27.546599 · Cited by 1
Jiménez, V., & Bosch, F. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch78 · Cited by 1
Sobral, M. V. S., Faria, H. S., Bendaham, L. C. A. R., Masiero, B. B., Gouvêa, C. A., Faria, G. D. S., dos Santos, M. D., Peres, C. D. A. P., Ovileira, L., & Souto, E. (2024) · doi:10.22541/au.171170096.61083292/v1
Rôle des hépatokines dans le dialogue inter-organes en physiologie et physiopathologie
Pacheco, A., & Postic, C. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.04.008
VIII. Drug Development and Clinical Trial Status for NASH/NAFLD
Minami, M. (2020) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.109.64
Bayoumi, A. (2020) · The Sydney eScholarship Repository (The University of Sydney)
Anti-fibrotic Therapy for Chronic Liver Diseases Review
Naser, M., Naser, M. M., & Shehata, L. H. (2021) · International Journal of Progressive Sciences and Technologies · doi:10.52155/ijpsat.v29.2.3730
Utilization of fault tree analysis techniques in fire protection work
Crass, E. R. (1986) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Triglyceride-Rich Lipoproteins
Bazarbashi, N., & Miller, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_12
Therapies for Alcohol-Related Liver Disease and for Non-Alcoholic Fatty Liver Disease
Yoshiji, H., Namisaki, T., Kaji, K., & Francque, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_19
Ogawa, K., Nakai, M., & Sakamoto, N. (2022) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.111.74
[Fibroblast growth factor (FGF) endocrines and pulmonary fibrogenesis].
Ghanem, M., Mailleux, A., & Crestani, B. (2023) · Revue des maladies respiratoires · doi:10.1016/j.rmr.2023.01.018
Metabolic-associated fatty liver disease: pharmacological management
Shi, Y., & Fan, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00010-0
Lü, C., Jin, L., Bi, J., Jin, H., You, X., Peng, L., Fan, H., Wang, H., Wang, L., Fan, Z., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1176136
Metadata
- Authors
- Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., Luo, Y., & Christian, R.
- Affiliations
- Virginia Commonwealth University (US)
- Bristol-Myers Squibb (United States) (US)
- University of California San Diego (US)
- Pinnacle Clinical Research (US)
- Duke University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Thomas Jefferson University (US)
- Corresponding author
- Charles, Edgar D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 392
- Issue
- 10165
- Pages
- 2705-2717
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2905440332
- Cited by
- 550
- References
- 43
- Citations by year
- 2026: 40 · 2025: 52 · 2024: 87 · 2023: 82 · 2022: 76 · 2021: 83 · 2020: 91 · 2019: 36 · 2018: 1
- FWCI
- 41.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- PEGylation, nonalcoholic steatohepatitis, hepatic fat fraction, liver fibrosis, obesity, type 2 diabetes, drug safety, drug efficacy, subcutaneous injection, liver disease treatment
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Fibroblast Growth Factors, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Polyethylene Glycols, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
